New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia Results served as basis for regulatory filing with U.S. Food and Drug Administration and designation as Priority Review

TITUSVILLE, N.J., March 29, 2015 /PRNewswire/ -- Three-month paliperidone palmitate, an investigational atypical antipsychotic, significantly delayed time to relapse compared to placebo in patients with schizophrenia, according to a new Phase 3 clinical study published this week in the Journal of the American Medical Association (JAMA) Psychiatry. Results of the study served as the basis for the recent New Drug Application (NDA) filing for three-month paliperidone palmitate injection to treat schizophrenia in adults with the U.S. Food and Drug Administration ("FDA") by Janssen Research & Development, LLC, ("Janssen"), the study sponsor. The FDA granted the filing Priority Review...